NO304790B1 - Analogifremgangsmaate for fremstilling av terapeutisk aktive azacykliske eller azabicykliske forbindelser - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive azacykliske eller azabicykliske forbindelser Download PDF

Info

Publication number: NO304790B1
Authority: NO; Norway
Prior art keywords: azabicyclo; mixture; residue; mol; evaporated
Prior art date: 1990-03-21

Application number

NO923203A

Other languages

English (en)

Norwegian (no)

Other versions

NO923646L (no

NO923646D0 (no

Inventor

John Stanley Ward

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-21

Filing date

1992-09-18

Publication date

1999-02-15

1992-09-18 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1992-09-18 Publication of NO923646D0 publication Critical patent/NO923646D0/no

1992-09-21 Publication of NO923646L publication Critical patent/NO923646L/no

1999-02-15 Publication of NO304790B1 publication Critical patent/NO304790B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 38
238000000034 method Methods 0.000 title claims abstract description 10
238000002360 preparation method Methods 0.000 title claims description 6
150000003839 salts Chemical class 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 2
235000015320 potassium carbonate Nutrition 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims 1
230000003920 cognitive function Effects 0.000 abstract description 9
210000001320 hippocampus Anatomy 0.000 abstract description 8
210000004129 prosencephalon Anatomy 0.000 abstract description 7
208000024827 Alzheimer disease Diseases 0.000 abstract description 6
241000124008 Mammalia Species 0.000 abstract description 5
239000000021 stimulant Substances 0.000 abstract description 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 101
239000002904 solvent Substances 0.000 description 101
239000000460 chlorine Substances 0.000 description 85
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
238000006243 chemical reaction Methods 0.000 description 68
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 62
239000000284 extract Substances 0.000 description 60
239000000243 solution Substances 0.000 description 52
238000005481 NMR spectroscopy Methods 0.000 description 46
238000004458 analytical method Methods 0.000 description 39
239000005457 ice water Substances 0.000 description 36
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
239000007787 solid Substances 0.000 description 36
239000007788 liquid Substances 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
238000001816 cooling Methods 0.000 description 28
238000010992 reflux Methods 0.000 description 28
238000004587 chromatography analysis Methods 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
239000012267 brine Substances 0.000 description 25
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 22
229920006395 saturated elastomer Polymers 0.000 description 21
239000011734 sodium Substances 0.000 description 21
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 19
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
MFORPJMYNKYBLR-UHFFFAOYSA-N 3-(3-chloropyrazin-2-yl)-1-methylpiperidin-3-ol Chemical compound C1N(C)CCCC1(O)C1=NC=CN=C1Cl MFORPJMYNKYBLR-UHFFFAOYSA-N 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
239000012458 free base Substances 0.000 description 14
150000003891 oxalate salts Chemical class 0.000 description 14
BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 12
239000003054 catalyst Substances 0.000 description 12
HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 10
238000001704 evaporation Methods 0.000 description 10
230000008020 evaporation Effects 0.000 description 10
238000004128 high performance liquid chromatography Methods 0.000 description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 8
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 8
NMRPBPVERJPACX-UHFFFAOYSA-N octan-3-ol Chemical compound CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
238000001953 recrystallisation Methods 0.000 description 7
229910052708 sodium Inorganic materials 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N CHCl3 Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
ZHVULPDNOFUIML-UHFFFAOYSA-N octane;hydrochloride Chemical compound Cl.CCCCCCCC ZHVULPDNOFUIML-UHFFFAOYSA-N 0.000 description 6
230000009870 specific binding Effects 0.000 description 6
230000003551 muscarinic effect Effects 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
PMBXCGGQNSVESQ-UHFFFAOYSA-N 1-Hexanethiol Chemical compound CCCCCCS PMBXCGGQNSVESQ-UHFFFAOYSA-N 0.000 description 4
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000003921 oil Substances 0.000 description 4
ZRKMQKLGEQPLNS-UHFFFAOYSA-N 1-Pentanethiol Chemical compound CCCCCS ZRKMQKLGEQPLNS-UHFFFAOYSA-N 0.000 description 3
GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 3
XJFYHQLJBJZAAY-UHFFFAOYSA-N 3-(3-butoxypyrazin-2-yl)-3-chloro-1-azabicyclo[2.2.2]octane;hydrochloride Chemical compound Cl.CCCCOC1=NC=CN=C1C1(Cl)C(CC2)CCN2C1 XJFYHQLJBJZAAY-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000004821 distillation Methods 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000012266 salt solution Substances 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 2
VLVSFBVSEMSLHV-UHFFFAOYSA-N 2-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-3-pentylsulfanylpyrazine;hydrochloride Chemical compound Cl.CCCCCSC1=NC=CN=C1C1=CCCN(C)C1 VLVSFBVSEMSLHV-UHFFFAOYSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
AWYZLHXZQCACQV-UHFFFAOYSA-N 2-chloro-3-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)pyrazine oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NC=CN=C1Cl AWYZLHXZQCACQV-UHFFFAOYSA-N 0.000 description 2
DRCWCFRJHTYROF-UHFFFAOYSA-N 2-hexylsulfanyl-3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)pyrazine;hydrochloride Chemical compound Cl.CCCCCCSC1=NC=CN=C1C1=CCCN(C)C1 DRCWCFRJHTYROF-UHFFFAOYSA-N 0.000 description 2
BHTZRHXQWWMGQH-UHFFFAOYSA-N 3-(3-hexoxypyrazin-2-yl)-1-azabicyclo[2.2.1]heptan-3-ol Chemical compound CCCCCCOC1=NC=CN=C1C1(O)C(C2)CCN2C1 BHTZRHXQWWMGQH-UHFFFAOYSA-N 0.000 description 2
QGKCEMLBQSDLFW-UHFFFAOYSA-N 3-chloro-3-(3-hexoxypyrazin-2-yl)-1-azabicyclo[2.2.1]heptane Chemical compound CCCCCCOC1=NC=CN=C1C1(Cl)C(C2)CCN2C1 QGKCEMLBQSDLFW-UHFFFAOYSA-N 0.000 description 2
RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
210000002932 cholinergic neuron Anatomy 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
-1 fatty acid monoglycerides Chemical class 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000000472 muscarinic agonist Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000011368 organic material Substances 0.000 description 2
230000001991 pathophysiological effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 2
239000010902 straw Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
VZPRMKOCTSUHCR-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-3-one Chemical compound C1CC2C(=O)CN1C2 VZPRMKOCTSUHCR-UHFFFAOYSA-N 0.000 description 1
SIKTVUHUQZNEPY-UHFFFAOYSA-N 1-methylpiperidin-3-one Chemical compound CN1CCCC(=O)C1 SIKTVUHUQZNEPY-UHFFFAOYSA-N 0.000 description 1
ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 1
JCMNMOBHVPONLD-UHFFFAOYSA-N 3,3,4,4,5,5,6,6,6-nonafluorohexan-1-ol Chemical compound OCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)F JCMNMOBHVPONLD-UHFFFAOYSA-N 0.000 description 1
CPWGWWRIEKOOLP-UHFFFAOYSA-N 3-(3-butylsulfanylpyrazin-2-yl)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound CCCCSC1=NC=CN=C1C1(O)C(CC2)CCN2C1 CPWGWWRIEKOOLP-UHFFFAOYSA-N 0.000 description 1
RMPHFVXVAKNLCP-UHFFFAOYSA-N 3-(3-butylsulfanylpyrazin-2-yl)-3-chloro-1-azabicyclo[2.2.2]octane Chemical compound CCCCSC1=NC=CN=C1C1(Cl)C(CC2)CCN2C1 RMPHFVXVAKNLCP-UHFFFAOYSA-N 0.000 description 1
HDEINBVFXGKBRR-UHFFFAOYSA-N 3-(3-heptoxypyrazin-2-yl)-1-azabicyclo[2.2.2]oct-2-ene Chemical compound CCCCCCCOC1=NC=CN=C1C1=CN2CCC1CC2 HDEINBVFXGKBRR-UHFFFAOYSA-N 0.000 description 1
HNASIFKDVQBBBP-UHFFFAOYSA-N 3-(3-pentoxypyrazin-2-yl)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound CCCCCOC1=NC=CN=C1C1(O)C(CC2)CCN2C1 HNASIFKDVQBBBP-UHFFFAOYSA-N 0.000 description 1
AILPARHTFHSAHO-UHFFFAOYSA-N 3-chloro-3-(3-pentoxypyrazin-2-yl)-1-azabicyclo[2.2.2]octane Chemical compound CCCCCOC1=NC=CN=C1C1(Cl)C(CC2)CCN2C1 AILPARHTFHSAHO-UHFFFAOYSA-N 0.000 description 1
BFLUTXDNFIYJHM-UHFFFAOYSA-N 5-chloropyrazine;lithium Chemical compound [Li]C1=NC=CN=C1Cl BFLUTXDNFIYJHM-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
OUWFQHPQHUCYRP-UHFFFAOYSA-N C(C(=O)O)(=O)O.CC=CCCCCC Chemical compound C(C(=O)O)(=O)O.CC=CCCCCC OUWFQHPQHUCYRP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
206010008674 Cholinergic syndrome Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
WKSXRWSOSLGSTN-UHFFFAOYSA-N Methoxypyrazine Chemical compound COC1=CN=CC=N1 WKSXRWSOSLGSTN-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
CQODGVQBRIGKLJ-UHFFFAOYSA-L [Na+].[Na+].[O-]OOO[O-] Chemical compound [Na+].[Na+].[O-]OOO[O-] CQODGVQBRIGKLJ-UHFFFAOYSA-L 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000007177 brain activity Effects 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
239000000064 cholinergic agonist Substances 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
KGZLFTWMCMEEJR-UHFFFAOYSA-N heptane;hydrochloride Chemical compound Cl.CCCCCCC KGZLFTWMCMEEJR-UHFFFAOYSA-N 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
YGKMWQSENKLXFE-UHFFFAOYSA-N octan-3-ol;hydrochloride Chemical compound Cl.CCCCCC(O)CC YGKMWQSENKLXFE-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940059574 pentaerithrityl Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
150000003216 pyrazines Chemical group 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000000926 separation method Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
210000004057 substantia innominata Anatomy 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
239000012085 test solution Substances 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NO923203A 1990-03-21 1992-09-18 Analogifremgangsmaate for fremstilling av terapeutisk aktive azacykliske eller azabicykliske forbindelser NO304790B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK072790A DK72790D0 (da)	1990-03-21	1990-03-21	Heterocycliske forbindelser, deres fremstilling og anvendelse
PCT/DK1991/000087 WO1991014686A1 (en)	1990-03-21	1991-03-20	Azacyclic or azabicyclic compounds, their preparation and use

Publications (3)

Publication Number	Publication Date
NO923646D0 NO923646D0 (no)	1992-09-18
NO923646L NO923646L (no)	1992-09-21
NO304790B1 true NO304790B1 (no)	1999-02-15

Family

ID=8096852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923203A NO304790B1 (no)	1990-03-21	1992-09-18	Analogifremgangsmaate for fremstilling av terapeutisk aktive azacykliske eller azabicykliske forbindelser

Country Status (18)

Country	Link
US (1)	US5182283A (da)
EP (1)	EP0521067B1 (da)
JP (2)	JPH05505811A (da)
AT (1)	ATE124409T1 (da)
AU (1)	AU660609B2 (da)
CA (1)	CA2078791A1 (da)
DE (1)	DE69110875T2 (da)
DK (2)	DK72790D0 (da)
ES (1)	ES2074714T3 (da)
FI (1)	FI924190A0 (da)
GR (1)	GR3017434T3 (da)
IE (1)	IE71515B1 (da)
IL (1)	IL97611A (da)
NO (1)	NO304790B1 (da)
NZ (1)	NZ237475A (da)
PT (1)	PT97099B (da)
WO (1)	WO1991014686A1 (da)
ZA (1)	ZA912122B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9201749D0 (en) *	1992-01-28	1992-03-11	Smithkline Beecham Plc	Medicaments
CA2237311A1 (en) *	1995-11-13	1997-05-22	Walter William Offen	Method for treating anxiety

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3048031A1 (de) *	1979-12-21	1981-09-17	Firmenich S.A., 1211 Genève	Verfahren zur herstellung substituierter pyrazine
US4859775A (en) *	1985-10-01	1989-08-22	Philip Morris Incorporated	Process for preparing acylpyrazine ethers
JPS6431779A (en) *	1987-07-28	1989-02-02	Hokuriku Pharmaceutical	Pyrazine derivative
IL88846A0 (en) *	1988-01-08	1989-07-31	Merck Sharp & Dohme	Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
NZ227684A (en) *	1988-01-30	1991-07-26	Merck Sharp & Dohme	Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
JPH02138179A (ja) *	1988-11-17	1990-05-28	Daiso Co Ltd	電荷移動錯体とその製造法
GB8918060D0 (en) *	1989-08-08	1989-09-20	Merck Sharp & Dohme	Therapeutic agents

1990
- 1990-03-21 DK DK072790A patent/DK72790D0/da unknown
1991
- 1991-03-15 IE IE86391A patent/IE71515B1/en not_active IP Right Cessation
- 1991-03-15 US US07/669,835 patent/US5182283A/en not_active Expired - Fee Related
- 1991-03-19 NZ NZ237475A patent/NZ237475A/en unknown
- 1991-03-20 DK DK91906725.6T patent/DK0521067T3/da active
- 1991-03-20 AU AU75744/91A patent/AU660609B2/en not_active Ceased
- 1991-03-20 AT AT91906725T patent/ATE124409T1/de not_active IP Right Cessation
- 1991-03-20 IL IL97611A patent/IL97611A/xx not_active IP Right Cessation
- 1991-03-20 WO PCT/DK1991/000087 patent/WO1991014686A1/en not_active Ceased
- 1991-03-20 ES ES91906725T patent/ES2074714T3/es not_active Expired - Lifetime
- 1991-03-20 CA CA002078791A patent/CA2078791A1/en not_active Abandoned
- 1991-03-20 FI FI924190A patent/FI924190A0/fi unknown
- 1991-03-20 JP JP91506762A patent/JPH05505811A/ja active Pending
- 1991-03-20 DE DE69110875T patent/DE69110875T2/de not_active Expired - Fee Related
- 1991-03-20 EP EP91906725A patent/EP0521067B1/en not_active Expired - Lifetime
- 1991-03-21 ZA ZA912122A patent/ZA912122B/xx unknown
- 1991-03-21 PT PT97099A patent/PT97099B/pt not_active IP Right Cessation
1992
- 1992-09-18 NO NO923203A patent/NO304790B1/no not_active IP Right Cessation
1995
- 1995-09-18 GR GR950402559T patent/GR3017434T3/el unknown
2000
- 2000-05-08 JP JP2000135085A patent/JP2000344765A/ja active Pending

Also Published As

Publication number	Publication date
JP2000344765A (ja)	2000-12-12
JPH05505811A (ja)	1993-08-26
NZ237475A (en)	1993-11-25
CA2078791A1 (en)	1991-09-22
DE69110875D1 (de)	1995-08-03
FI924190A7 (fi)	1992-09-18
IL97611A (en)	1997-06-10
ATE124409T1 (de)	1995-07-15
NO923646L (no)	1992-09-21
IL97611A0 (en)	1992-06-21
PT97099A (pt)	1991-12-31
EP0521067B1 (en)	1995-06-28
EP0521067A1 (en)	1993-01-07
DK0521067T3 (da)	1995-11-06
GR3017434T3 (en)	1995-12-31
AU7574491A (en)	1991-10-21
DK72790D0 (da)	1990-03-21
ES2074714T3 (es)	1995-09-16
FI924190L (fi)	1992-09-18
NO923646D0 (no)	1992-09-18
US5182283A (en)	1993-01-26
DE69110875T2 (de)	1996-03-21
FI924190A0 (fi)	1992-09-18
ZA912122B (en)	1991-12-24
WO1991014686A1 (en)	1991-10-03
AU660609B2 (en)	1995-07-06
IE910863A1 (en)	1991-09-25
PT97099B (pt)	1998-08-31
IE71515B1 (en)	1997-02-12

Legal Events

Date	Code	Title	Description
2002-11-04	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN SEPTEMBER 2002

Publication	Publication Date	Title
JP3100160B2 (ja)	2000-10-16	複素環式化合物、その調製方法およびその用途
KR100344329B1 (ko)	2002-11-30	아자비사이클릭화합물,이의제조방법및이를함유하는약제학적조성물
DE60005054T2 (de)	2004-07-08	Chinuclidin-acrylamide
EP0687265B1 (en)	2002-01-23	Heterocyclic compounds and their preparation and use
DE69114848T2 (de)	1996-07-18	Heterozyklische verbindungen, ihre herstellung und anwendung.
DE69111138T2 (de)	1995-11-30	Heterocyclische Verbindungen mit antiemetischer und Migräne unterdrückender Wirkung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen.
DE69329018T2 (de)	2001-03-22	Heterocyclische verbindungen, deren herstellung und verwendung
IE83352B1 (en)		Isoxazole and isothiazole compounds that enhance cognitive function
EP3307741A1 (de)	2018-04-18	Positiv allosterische modulatoren des muskarinergen m2 rezeptors
AU2009352490B2 (en)	2013-06-20	1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands
US5527813A (en)	1996-06-18	Heterocyclic compounds and their preparation and use
NO304790B1 (no)	1999-02-15	Analogifremgangsmaate for fremstilling av terapeutisk aktive azacykliske eller azabicykliske forbindelser
NO163099B (no)	1989-12-27	Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepin-6-on-derivater.
US5641791A (en)	1997-06-24	Heterocyclic compounds and their preparation and use
CN104592233A (zh)	2015-05-06	用于治疗神经变性和神经精神紊乱的桥头胺环稠合吲哚和二氢吲哚
NO178303B (no)	1995-11-20	Analogifremgangsmåte for fremstilling av terapeutisk aktive kinuklidinforbindelser